Walk-In Interviews for FRESHERS on 18th Oct’ 2020

Walk-in interview  for freshers on 18th Oct’ 2020 Hetero Labs Limited

HETERO Walk-in interview for freshers on 18-10-2020 (Sunday).

Company Website : Hetro labs limited 

At Hetero Corporate office, Sanathnagar, Hyderabad-18 Land mark Opp: Sanathnagar Police station.

ప్రముఖ ఫార్మా కంపెనీ హెటిరో ప్రోడక్షన్( Production) విభాగం లో నియామకాల కోసం ఇంటర్వులు నిర్వహిస్తుంది.
B.Sc Chemistry., BCOm.,B.A., Intermediate. అర్హత కలిగిన పురుష అభ్యర్థులు మాత్రమే అర్హులు.
Age Below 28 years.
ఆసక్తి గల అబ్యర్దులు
హెటేరో కార్పొరెట్‌ కార్యలయం సనత్ నగర్ ,హైద్రాబాద్ నందు 18-10-2020 అదివారం జరిగే ఇంటర్వులకు హాజరు కాగలరు. అర్హత పొందిన అభ్యర్థులకు జీతంతో పాటు PF, ESI, అలవెన్సులు, వార్షిక బోనస్, Increment, ఇన్సూరెన్స్, సబ్సిడీ Canteen, Transportation సౌకర్యం ఉంటుంది.


K.Praveen HR

Hetero labs ltd.

Walk-In Interviews for FRESHERS

Hetro labs invites Walk-in interview  for freshers for production department eligible candidate can attend Walk-in interview

About Company :

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS.

Backed by over 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Generics, Biosimilars, Custom Pharmaceutical services and Branded Generics.

The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products.

Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, audited and approved by stringent regulatory authorities like US FDA, EU, TGA-Australia, MCC-South Africa and others.

Our portfolio includes 300 plus products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology and Immunology etc.

Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide.